Century Therapeutics shares nonclinical data for iPSC-derived diabetes therapy

Century Therapeutics, Inc. (NASDAQ: IPSC) presented nonclinical data for its iPSC-derived islet replacement therapy, CNTY-813, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, on Oct. 2, 2026.

The data covered scalable manufacturing, in vivo function, and immune evasion for CNTY-813, which is engineered with the company's Allo-Evasion 5.0 technology and is being developed as a treatment for type 1 diabetes.

In a study lasting over eleven months, CNTY-813 maintained glycemic control in a diabetic mouse model until graft removal. All mice administered with CNTY-813 achieved normoglycemia. The therapy showed glucose-stimulated insulin secretion potency similar to primary islets.

Five clinical-scale manufacturing batches produced consistent final product profiles across a 29-day process that exceeded purity criteria at every stage. In rats, CNTY-813 islets were confirmed engrafted in the liver one month after transplant via the planned clinical route of liver portal vein delivery. Separately, mice transplanted with clinical-scale islets after 96 hours of cold storage normalized blood glucose within 30 days and maintained normoglycemia through three months of follow-up.

Century stated it reached general alignment with the U.S. Food and Drug Administration on its nonclinical package, Phase 1 manufacturing process, and proposed Phase 1/2 trial design following a pre-IND meeting.

"We remain on track to submit the CNTY-813 IND in the fourth quarter of this year with initial clinical data anticipated in the second half of 2027," said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics.

The IND submission for CNTY-813 remains subject to the completion of remaining IND-enabling studies. Initial safety and early efficacy data from the first-in-human study are anticipated in the second half of 2027.

You May Also Be Interested In

• FDA lifts clinical hold on Arbutus Biopharma's AB-101 drug candidate
• Karbon-X reports Q1 FY2027 results with gross margin at 32%
• FDA accepts Biohaven's troriluzole NDA resubmission for rare disease